Breast Cancer
Conditions
Brief summary
The purpose of this study is to investigate and analyse genomic profiles in patient with breast cancer who failed standard treatment, refractory and young breast cancer.
Detailed description
The hypothesis is that genomic profiling measured by CancerSCAN, cfDNA, Whole exome sequencing (WES), Whole transcriptome sequencing (WTS), FACS(Fluorescence-Activated Cell Sorting), cytokine and immunologic signature analysis would be helpful to find out tolerance for chemotherapy and innovate new therapeutic strategies.
Interventions
None listed
Sponsors
Samsung Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically or cytologically confirmed breast cancer that is either metastatic or young breast cancer(≤ 40 years of age). 2. HER2 positive patient who failed HER2 target therapy including trastuzumab with feasible biopsy site. 3. Triple Negative Breast Cancer patient who failed standard therapy with feasible biopsy site. 4. Hormone Receptor positive patient who failed standard therapy with feasible biopsy site. 5. Age ≥ 21 years 6. Written informed consent
Exclusion criteria
1. No feasible biopsy site 2. No written informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants With Mutated Genes and/or Abnormal Gene expression and/or Different Immune signature That Affect to Treatment Outcome. | 1 year |
Countries
South Korea
Contacts
Primary ContactYoung-hyuck Im, MD, Ph.D
Outcome results
None listed